AstraZeneca PLC
ZEG
Company Profile
Business description
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
96,100
Stocks News & Analysis
stocks
Investor Playbook: What Transurban, APA and Deterra have in common?
What inflation-resistant businesses have in common.
stocks
Our view after REA’s share price rally
A bullish market reaction but valuation concerns remain.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,128.60 | 16.10 | -0.18% |
| CAC 40 | 8,139.00 | 66.37 | -0.81% |
| DAX 40 | 25,820.36 | 504.65 | -1.92% |
| Dow JONES (US) | 51,285.73 | 237.33 | -0.46% |
| FTSE 100 | 10,673.94 | 108.72 | -1.01% |
| HKSE | 24,666.73 | 184.87 | 0.76% |
| NASDAQ | 24,579.43 | 264.43 | 1.09% |
| Nikkei 225 | 59,277.63 | 1,842.86 | 3.21% |
| NZX 50 Index | 13,932.44 | 66.06 | -0.47% |
| S&P 500 | 7,376.86 | 23.13 | 0.31% |
| S&P/ASX 200 | 8,993.70 | 27.10 | -0.30% |
| SSE Composite Index | 3,675.23 | 26.05 | 0.71% |